Drug companies get over $1 billion in flu vaccine funding

Share this article:
The US government awarded over $1 billion to five drug manufacturers developing technology for quicker mass production of vaccines in the event of an avian flu pandemic. The companies are GlaxoSmithKline, $274.8 million; MedImmune, $169.5 million; Novartis Vaccines and Diagnostics, $220.5 million; DynPort Vaccine, $41 million; and Solvay Pharmaceuticals, $298.6 million. The contracts cover a five-year period. The money comes from the $3.8 billion that congress approved last year with the goal of being to distribute vaccine to every American within six months of a pandemic striking. Davis Stout, president of pharmaceutical operations at GlaxoSmithKline, told the Associated Press vaccine makers are about three to five years away from growing flu vaccines in large laboratory vats, rather than the current production technique inside specialized chicken eggs. “What this funding does is accelerate the speed in which we can do the work,” he said.
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.